Addex Therapeutics (ADXN) Competitors $8.11 -0.90 (-9.99%) As of 10:22 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADXN vs. COEP, MAAQ, ALGS, RANI, PULM, DYAI, KZR, MRNS, ALXO, and BCABShould you be buying Addex Therapeutics stock or one of its competitors? The main competitors of Addex Therapeutics include Coeptis Therapeutics (COEP), Mana Capital Acquisition (MAAQ), Aligos Therapeutics (ALGS), Rani Therapeutics (RANI), Pulmatrix (PULM), Dyadic International (DYAI), Kezar Life Sciences (KZR), Marinus Pharmaceuticals (MRNS), ALX Oncology (ALXO), and BioAtla (BCAB). These companies are all part of the "pharmaceutical products" industry. Addex Therapeutics vs. Its Competitors Coeptis Therapeutics Mana Capital Acquisition Aligos Therapeutics Rani Therapeutics Pulmatrix Dyadic International Kezar Life Sciences Marinus Pharmaceuticals ALX Oncology BioAtla Coeptis Therapeutics (NASDAQ:COEP) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking, media sentiment and dividends. Do insiders and institutionals hold more shares of COEP or ADXN? 13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by insiders. Comparatively, 15.0% of Addex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts recommend COEP or ADXN? Addex Therapeutics has a consensus target price of $30.00, indicating a potential upside of 269.91%. Given Addex Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Addex Therapeutics is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Addex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, COEP or ADXN? Coeptis Therapeutics has a beta of -0.59, suggesting that its stock price is 159% less volatile than the S&P 500. Comparatively, Addex Therapeutics has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Does the media refer more to COEP or ADXN? In the previous week, Addex Therapeutics had 3 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 4 mentions for Addex Therapeutics and 1 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 1.87 beat Addex Therapeutics' score of 0.64 indicating that Coeptis Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Coeptis Therapeutics Very Positive Addex Therapeutics Positive Does the MarketBeat Community prefer COEP or ADXN? Addex Therapeutics received 10 more outperform votes than Coeptis Therapeutics when rated by MarketBeat users. However, 71.43% of users gave Coeptis Therapeutics an outperform vote while only 51.72% of users gave Addex Therapeutics an outperform vote. CompanyUnderperformOutperformCoeptis TherapeuticsOutperform Votes571.43% Underperform Votes228.57% Addex TherapeuticsOutperform Votes1551.72% Underperform Votes1448.28% Which has preferable earnings & valuation, COEP or ADXN? Addex Therapeutics has higher revenue and earnings than Coeptis Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoeptis Therapeutics$62.87K487.92-$21.27M-$5.80-1.51Addex Therapeutics$404.10K21.27-$11.76M-$0.34-23.85 Is COEP or ADXN more profitable? Addex Therapeutics has a net margin of 850.30% compared to Coeptis Therapeutics' net margin of 0.00%. Addex Therapeutics' return on equity of -112.43% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coeptis TherapeuticsN/A -1,094.50% -219.97% Addex Therapeutics 850.30%-112.43%-77.95% SummaryAddex Therapeutics beats Coeptis Therapeutics on 13 of the 18 factors compared between the two stocks. Get Addex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXN vs. The Competition Export to ExcelMetricAddex TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.60M$6.93B$5.60B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-23.858.8527.2320.02Price / Sales21.27256.44417.65154.33Price / CashN/A65.8538.2534.64Price / Book6.766.617.124.70Net Income-$11.76M$143.93M$3.23B$247.97M7 Day Performance-0.50%3.84%2.74%2.64%1 Month Performance4.38%11.14%8.94%6.39%1 Year Performance-4.59%4.35%31.59%13.95% Addex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXNAddex Therapeutics2.528 of 5 stars$8.11-10.0%$30.00+269.9%-1.2%$8.60M$404.10K-23.8530Gap DownCOEPCoeptis Therapeutics1.4063 of 5 stars$9.30+1.6%N/A+49.6%$32.68M$62.87K-1.602Positive NewsMAAQMana Capital AcquisitionN/A$3.99-5.2%N/A+716.2%$32.42MN/A0.001ALGSAligos Therapeutics4.5073 of 5 stars$5.25-0.8%$70.00+1,233.3%-39.4%$32.10M$3.27M-0.3990Positive NewsGap UpRANIRani Therapeutics2.0098 of 5 stars$0.56-0.4%$9.40+1,587.6%-85.7%$32.02M$1.20M-0.53110PULMPulmatrix0.4346 of 5 stars$8.58-4.5%N/A+334.2%$31.32M$1.92M-3.2520Gap DownDYAIDyadic International2.2443 of 5 stars$1.02-1.6%$6.00+488.2%-55.2%$30.69M$3.34M-4.437Gap DownKZRKezar Life Sciences4.5772 of 5 stars$4.37+4.5%$39.50+803.9%-33.8%$30.54M$7M-0.3360Positive NewsMRNSMarinus Pharmaceuticals2.033 of 5 stars$0.55-0.2%$4.79+771.6%-64.8%$30.32M$30.99M-0.22110ALXOALX Oncology2.705 of 5 stars$0.56+15.1%$3.30+490.7%-93.6%$29.83MN/A-0.1940News CoverageAnalyst RevisionGap UpBCABBioAtla2.8343 of 5 stars$0.51+24.7%$5.00+880.4%-71.4%$29.79M$11M-0.3060Gap DownHigh Trading Volume Related Companies and Tools Related Companies Coeptis Therapeutics Alternatives Mana Capital Acquisition Alternatives Aligos Therapeutics Alternatives Rani Therapeutics Alternatives Pulmatrix Alternatives Dyadic International Alternatives Kezar Life Sciences Alternatives Marinus Pharmaceuticals Alternatives ALX Oncology Alternatives BioAtla Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADXN) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Addex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADXN Stock Free ADXN Stock Alerts